Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 2 de 2
2.
Diagn Microbiol Infect Dis ; 105(2): 115857, 2023 Feb.
Article En | MEDLINE | ID: mdl-36436310

An increase of carbapenemase-producing Bacteroides fragilis infections is observed. To detect such a resistance in B. fragilis, several tests exist that are expensive or show poor sensitivity and specificity. Therefore, we upgraded the Anaerobic Carbapenem Inactivation Method (Ana-CIM) to easily screen for carbapenemase-producing B. fragilis. The presence of carbapenemase cfiA gene was identified in 50 B. fragilis isolates by PCR. We modified the Ana-CIM by (1) increasing the bacterial inoculum, and (2) measuring the differences in diameter between the negative control and the testing disc. We correctly classified the cfiA-negative and positive isolates and could define a cut-off of positivity at 2 mm. Our modified Ana-CIM allowed to correctly discriminate the 31 cfiA-positive with meropenem MICs ranging from 1 to > 32 µg/mL. We anticipate that our modified Ana-CIM could be used in most clinical laboratories to easily screen for carbapenemase-producing B. fragilis, even at low levels.


Bacterial Proteins , Bacteroides fragilis , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Bacteroides fragilis/enzymology , Bacteroides fragilis/genetics , Carbapenems/pharmacology
...